Institution
Guy's and St Thomas' NHS Foundation Trust
Healthcare•London, United Kingdom•
About: Guy's and St Thomas' NHS Foundation Trust is a healthcare organization based out in London, United Kingdom. It is known for research contribution in the topics: Population & Medicine. The organization has 7686 authors who have published 9631 publications receiving 399353 citations. The organization is also known as: Guy's and St Thomas' National Health Service Foundation Trust & Guy's and St Thomas' National Health Service Trust.
Topics: Population, Medicine, Randomized controlled trial, Cancer, Breast cancer
Papers published on a yearly basis
Papers
More filters
••
Vanderbilt University Medical Center1, Vanderbilt University2, University of Pennsylvania3, National Institute for Health Research4, Queen Mary University of London5, Veterans Health Administration6, Emory University7, VA Boston Healthcare System8, Imperial College London9, University of Ioannina10, University of Leicester11, University of Bordeaux12, University of Michigan13, University of Cambridge14, McMaster University15, COMSATS Institute of Information Technology16, University of Dundee17, University of Newcastle18, Lund University19, Leiden University Medical Center20, University Medical Center Groningen21, University of Edinburgh22, Guy's and St Thomas' NHS Foundation Trust23, King's College London24, University of Texas Health Science Center at Houston25, University of Liverpool26, Broad Institute27, Boston University28, University of London29, University of Bristol30, Washington University in St. Louis31, university of lille32, Wellcome Trust Centre for Human Genetics33, University of Eastern Finland34, Wellcome Trust Sanger Institute35, National Institutes of Health36, Population Health Research Institute37, Brigham and Women's Hospital38, University of Sassari39, Wellcome Trust40, University of Oxford41, Harokopio University42, University of Washington43, Harvard University44, VA Palo Alto Healthcare System45, Stanford University46
TL;DR: Analysis of blood pressure data from the Million Veteran Program trans-ethnic cohort identifies common and rare variants, and genetically predicted gene expression across multiple tissues associated with systolic, diastolic and pulse pressure in over 775,000 individuals.
Abstract: In this trans-ethnic multi-omic study, we reinterpret the genetic architecture of blood pressure to identify genes, tissues, phenomes and medication contexts of blood pressure homeostasis. We discovered 208 novel common blood pressure SNPs and 53 rare variants in genome-wide association studies of systolic, diastolic and pulse pressure in up to 776,078 participants from the Million Veteran Program (MVP) and collaborating studies, with analysis of the blood pressure clinical phenome in MVP. Our transcriptome-wide association study detected 4,043 blood pressure associations with genetically predicted gene expression of 840 genes in 45 tissues, and mouse renal single-cell RNA sequencing identified upregulated blood pressure genes in kidney tubule cells.
310 citations
••
TL;DR: This guideline is intended to assist in the clinical care of patients with suspected or confirmed ICED infection in the UK, to inform local infection prevention and treatment policies and guidelines and to be used in the development of educational and training material by the relevant professional societies.
Abstract: Infections related to implantable cardiac electronic devices (ICEDs), including pacemakers, implantable cardiac defibrillators and cardiac resynchronization therapy devices, are increasing in incidence in the USA and are likely to increase in the UK, because more devices are being implanted. These devices have both intravascular and extravascular components and infection can involve the generator, device leads and native cardiac structures or various combinations. ICED infections can be life-threatening, particularly when associated with endocardial infection, and all-cause mortality of up to 35% has been reported. Like infective endocarditis, ICED infections can be difficult to diagnose and manage. This guideline aims to (i) improve the quality of care provided to patients with ICEDs, (ii) provide an educational resource for all relevant healthcare professionals, (iii) encourage a multidisciplinary approach to ICED infection management, (iv) promote a standardized approach to the diagnosis, management, surveillance and prevention of ICED infection through pragmatic evidence-rated recommendations, and (v) advise on future research projects/audit. The guideline is intended to assist in the clinical care of patients with suspected or confirmed ICED infection in the UK, to inform local infection prevention and treatment policies and guidelines and to be used in the development of educational and training material by the relevant professional societies. The questions covered by the guideline are presented at the beginning of each section.
310 citations
••
European Institute of Oncology1, Netherlands Cancer Institute2, Autonomous University of Barcelona3, International Agency for Research on Cancer4, Newcastle University5, NHS Greater Glasgow and Clyde6, University of Cologne7, Cancer Research UK8, University College London9, Mario Negri Institute for Pharmacological Research10, University of Lausanne11, St James's University Hospital12, Ministero della Salute13, Office for National Statistics14, Guy's and St Thomas' NHS Foundation Trust15, Université Paris-Saclay16, Queen Mary University of London17, Russian Academy18, Curie Institute19, German Cancer Research Center20
TL;DR: P. Boyle*, P. Boffetta, J. Burn, H. Burns, L. Levi, G. McVie, P. Quinn, M. Richards, U. Scully, E. Storm,M.
308 citations
••
TL;DR: After accounting for relevant covariates, ustekinumab had the highest first-course drug survival, and will aid clinical decision making when choosing biologic therapy for psoriasis patients.
304 citations
••
TL;DR: To assess current trajectories towards the GPW13 UHC billion target—1 billion more people benefiting from UHC by 2023—the authors estimated additional population equivalents with UHC effective coverage from 2018 to 2023, and quantified frontiers of U HC effective coverage performance on the basis of pooled health spending per capita.
304 citations
Authors
Showing all 7765 results
Name | H-index | Papers | Citations |
---|---|---|---|
Christopher J L Murray | 209 | 754 | 310329 |
Bruce M. Psaty | 181 | 1205 | 138244 |
Giuseppe Remuzzi | 172 | 1226 | 160440 |
Mika Kivimäki | 166 | 1515 | 141468 |
Simon I. Hay | 165 | 557 | 153307 |
Theo Vos | 156 | 502 | 186409 |
Ali H. Mokdad | 156 | 634 | 160599 |
Steven Williams | 144 | 1375 | 86712 |
Igor Rudan | 142 | 658 | 103659 |
Mohsen Naghavi | 139 | 381 | 169048 |
Christopher D.M. Fletcher | 138 | 674 | 82484 |
Martin McKee | 138 | 1732 | 125972 |
David A. Jackson | 136 | 1095 | 68352 |
Graham G. Giles | 136 | 1249 | 80038 |
Yang Liu | 129 | 2506 | 122380 |